
	Three Months Ended March 31, 2025								Three Months Ended March 31, 2024
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	24	%	—	%	—	%	24	%	25	%	—	%	—	%	25	%
Patients	10	%	—	%	—	%	10	%	10	%	—	%	—	%	10	%
Medicare and Medicaid	8	%	—	%	—	%	8	%	8	%	—	%	—	%	8	%
Third party	36	%	—	%	—	%	36	%	35	%	—	%	—	%	35	%
Total Dx revenues by payer	78	%	—	%	—	%	78	%	78	%	—	%	—	%	78	%
BLS




Pharmaceutical, biotechnology, and medical device companies	9	%	9	%	4	%	22	%	9	%	9	%	4	%	22	%
Total Revenues	87	%	9	%	4	%	100	%	87	%	9	%	4	%	100	%

Revenues in the United States (U.S.) were $2,813.8 (84.1%) and $2,654.6 (83.6%) for the three months ended March 31, 2025, and 2024, respectively.

The following table provides information about accounts receivable, unbilled services, and unearned revenue from contracts with customers:


	March 31, 2025		December 31, 2024
Dx accounts receivable	$	1,403.2	$	1,259.3
BLS accounts receivable	758.6		729.5
Less BLS allowance for credit losses	(38.6)		(44.7)
Accounts receivable, net	$	2,123.2	$	1,944.1

Gross unbilled services	$	158.8	$	160.5
Less reserve for unbilled services	(7.5)		(7.6)
Unbilled services	$	151.3	$	152.9

Revenues recognized during the period that were included in the unearned revenue balance at the beginning of the period were $68.9 and $51.0 for the three months ended March 31, 2025, and 2024, respectively.

BLS estimates future expected credit losses on accounts receivable and unbilled services over the remaining collection period of the instrument. The rollforward for the allowance for credit losses is as follows:


	Accounts Receivable		Unbilled Services		Total
Allowance for credit losses at December 31, 2024	$	44.7	$	7.6	$	52.3
Write offs	(6.8)		(0.2)		(7.0)
Foreign currency impact	0.7		0.1		0.8
Allowance for credit losses at March 31, 2025	$	38.6	$	7.5	$	46.1